MaxCyte reported a total revenue of $10.4 million for the first quarter of 2025, an 8% decrease compared to the same period in 2024. However, core business revenue increased by 1% to $8.2 million. The company added one new SPL client, TG Therapeutics, bringing the total number of active SPLs to 29. Net loss for the quarter was $10.3 million.
Total revenue for Q1 2025 was $10.4 million, an 8% decrease from Q1 2024.
Core business revenue increased by 1% to $8.2 million in Q1 2025.
Strategic Platform License (SPL) Program-related revenue decreased by 32% to $2.1 million.
MaxCyte added one new SPL client, TG Therapeutics, bringing the total active SPLs to 29.
MaxCyte reiterates its 2025 revenue guidance, expecting core revenue to grow 8% to 15% compared to 2024, and SPL Program-related revenue to be approximately $5 million for the year. The company anticipates ending 2025 with approximately $160 million in total cash, cash equivalents, and investments.
Visualization of income flow from segment revenue to net income